Analyst Price Target is $9.00
▲ +154.96% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for OptiNose in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 154.96% upside from the last price of $3.53.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in OptiNose. This Buy consensus rating has held steady for over two years.
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.